Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IRI data

This article was originally published in The Tan Sheet

Executive Summary

Metabolife 356's expansion into retail channels yields second-place ranking among top 15 new consumer products in 2000-2001, according to 1Nov. 1 Information Resources, Inc. statement. Ephedra-containing supplement debuted in food, drug and mass channels in August 2000. Product's first-year retail sales were $215 mil., IRI reports. Rexall's Metab-O-Lite placed sixth with sales of $110 mil. Unilever's Dove deodorant took 12th place with sales of $71 mil...

You may also be interested in...



Metabolife Ephedra-Free Snack Bars Will Target Consumers With Sampling

Metabolife International's $2.4 mil. product sampling effort for its new nutrition bars will include co-packaging the bars with the company's flagship Metabolife 356 product

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 

Topics

UsernamePublicRestriction

Register

PS093260

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel